Melanotan I vs Melanotan II: Differences and Mechanisms of Action

EXOMA Scientific Team · Publicado el 13 de abril de 2026 · Actualizado el 18 de agosto de 2026

Scientific comparison between Melanotan I and Melanotan II: structure, receptor selectivity MC1R-MC5R, mechanisms of action and pharmacological profile.

Introduction to α-MSH Analogs

Melanotan I (Afamelanotide) and Melanotan II are synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH), originally developed at the University of Arizona in the 1990s. Although they share a common origin, they present significant differences in their pharmacology.

Molecular Structure

Melanotan I (MT-I / Afamelanotide)

• Structure: Linear analog of α-MSH with 13 amino acids
• Sequence: [Nle4, D-Phe7]-α-MSH
• Modifications: Substitution of Met4 by Nle4 and L-Phe7 by D-Phe7
• Molecular weight: ~1646 Da
• Stability: Greater resistance to enzymatic degradation than native α-MSH

Melanotan II (MT-II)

• Structure: Cyclic heptapeptide analog
• Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
• Modifications: Cyclization that confers greater stability and potency
• Molecular weight: ~1024 Da
• Stability: Highly resistant to proteases due to its cyclic structure

Melanocortin Receptor Selectivity

The fundamental difference between MT-I and MT-II lies in their selectivity for the melanocortin receptors (MCR):

MC1R: The Pigmentation Receptor

Both analogs activate MC1R in melanocytes, stimulating:

1. Activación de adenilato ciclasa → aumento de cAMP
2. Activación de PKA (proteína quinasa A)
3. Fosforilación de CREB
4. MITF expression (microphthalmia-associated transcription factor)
5. Transcripción de tirosinasa y enzimas melanogénicas
6. Cambio de feomelanina (amarillo/rojo) a eumelanina (café/negro)

MC4R: The Key Difference

MT-II shows high affinity for MC4R, which explains its additional effects:

• Appetite regulation: Hypothalamic MC4R modulates satiety signaling
• Sexual function: MC4R in brain areas involved in the sexual response
• Energy homeostasis: Regulation of basal energy expenditure

MT-I, being more selective for MC1R, has an effects profile more focused on pigmentation.

Mechanism of Melanogenesis

The pigmentation process induced by both peptides follows the cascade:

1. MC1R binding en melanocitos epidérmicos
2. Signaling via Gs → activación de adenilato ciclasa
3. Increase in cAMP intracelular
4. Activation of PKA → fosforilación de CREB
5. Expression of MITF → master factor of melanogenesis
6. Upregulation of tyrosinase → enzima limitante de la síntesis de melanina
7. Conversion of tyrosine → DOPA → dopaquinone → eumelanina
8. Melanosome transfer to surrounding keratinocytes

Comparative Pharmacokinetics

Regulatory Status

Melanotan I (Afamelanotide)

• EMA approval: 2014 for erythropoietic protoporphyria (EPP)
• FDA approval: 2019 for EPP
• Therapeutic mechanism: Photoprotection through increased eumelanin

Melanotan II

• State: Research compound without regulatory approval
• Approved derivative: Bremelanotide (PT-141), an MT-II derivative approved by the FDA (2019) for female sexual dysfunction

Current Research

Photoprotection and Dermatology

• Studies on the prevention of UV damage in high-risk populations
• Research in vitiligo and pigmentation disorders
• Evaluation of photoprotective effects in models of cutaneous carcinogenesis

Neuroscience

• Role of MC4R in feeding behavior
• Modulation of dopaminergic reward circuits
• Neuroprotective effects of melanocortinergic signaling

Considerations for Research

When selecting between MT-I and MT-II for research:

• MT-I: Ideal for studies focused on melanogenesis and MC1R
• MT-II: More appropriate for research on MC3R/MC4R and its pleiotropic effects
• Both: Require storage at -20°C and reconstitution with bacteriostatic water

Conclusion

Melanotan I and II, although analogs of the same endogenous precursor, represent distinct pharmacological tools. MT-I offers MC1R selectivity with a more focused profile, while MT-II provides pan-melanocortinergic activity with effects on multiple physiological systems.

Exoma Peptides offers both compounds with certified purity and certificate of analysis (COA) included.

References

Material for research use only. Verified primary sources supporting the scientific claims of this article:

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754. PMID 6777774. (animal / in vitro — síntesis y bioensayo)
2. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32(12):2555-2561. doi:10.1021/jm00132a010. PMID 2555512. (in vitro / animal — diseño y bioensayo)
3. Hadley ME, Abdel-Malek ZA, Marwan MM, Kreutzfeld KL, Hruby VJ. [Nle4, D-Phe7]-alpha-MSH: a superpotent melanotropin that "irreversibly" activates melanoma tyrosinase. Endocr Res. 1985;11(3-4):157-170. doi:10.1080/07435808509032974. PMID 3009169. (in vitro — mecanismo)
4. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12(Suppl 4):S74-S79. doi:10.1038/sj.ijir.3900582. PMID 11035391. (humano — ensayo cruzado doble ciego)
5. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. doi:10.1056/NEJMoa1411481. PMID 26132941. (human — randomized, double-blind, placebo-controlled clinical trials)

Products available at EXOMA

• Melanotan I
• Melanotan II